<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875615</url>
  </required_header>
  <id_info>
    <org_study_id>UMIAMI-20080793</org_study_id>
    <secondary_id>SCCC-2007101</secondary_id>
    <secondary_id>BAYER-SCCC-2007101</secondary_id>
    <nct_id>NCT00875615</nct_id>
  </id_info>
  <brief_title>Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami Sylvester Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami Sylvester Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor. Infusing chemotherapy
      directly into the liver and giving it together with sorafenib may kill more tumor cells.

      PURPOSE: This phase II trial is studying the side effects of infusing cisplatin or
      carboplatin directly into the liver and giving it together with sorafenib in treating
      patients with liver cancer that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the safety of intrahepatic arterial infusion of cisplatin or carboplatin in
           combination with sorafenib tosylate in patients with unresectable hepatocellular
           carcinoma.

      Secondary

        -  To assess the time to tumor progression in patients treated with this regimen.

        -  To assess the overall and progression-free survival of patients treated with this
           regimen.

      OUTLINE: Patients receive intrahepatic arterial infusion of cisplatin or carboplatin over
      30-45 minutes on day 1 and oral sorafenib tosylate twice daily on days 8-35. Treatment
      repeats every 42 days for up to 12 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of subjects experiencing adverse events after receiving protocol therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Clinical Benefit</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients achieving complete or partial response according to RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin or Carboplatin + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
    <arm_group_label>Cisplatin or Carboplatin + Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
    <arm_group_label>Cisplatin or Carboplatin + Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.</description>
    <arm_group_label>Cisplatin or Carboplatin + Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed hepatocellular carcinoma (HCC) OR serum alpha fetoprotein ≥
             400 ng/mL with radiological evidence suggestive of HCC

               -  Unresectable disease

          -  Child-Pugh class A or selected Child-Pugh class B disease (Child-Pugh score ≤ 7
             points)

               -  No Child-Pugh class C disease

          -  No disease outside the liver or macroscopic invasion of the major vessels such as the
             portal vein

          -  No known brain metastasis

               -  Patients with neurological symptoms must undergo CT scan or MRI of the brain

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC ≥ 3,000/mm³ (for patients scheduled to receive carboplatin) or ≥ 2,000/mm³ (for
             patients scheduled to receive cisplatin)

          -  Platelet count ≥ 100,000/mm³ (for patients scheduled to receive carboplatin) or ≥
             60,000/mm³ (for patients scheduled to receive cisplatin)

          -  Serum creatinine ≤ 1.9 mg/dL (for patients scheduled to receive carboplatin) or ≤ 1.5
             mg/dL (for patients scheduled to receive cisplatin)

          -  Serum total bilirubin ≤ 3 mg/dL

          -  AST and ALT &lt; 5 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 3 months after
             completion of study treatment

          -  No cardiac disease, including any of the following:

               -  NYHA class III-IV congestive heart failure

               -  Unstable angina (anginal symptoms at rest)

               -  New onset of angina within the past 3 months

               -  Myocardial infarction within the past 6 months

               -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  No uncontrolled hypertension, defined as systolic BP &gt; 150 mm Hg or diastolic BP &gt; 90
             mm Hg, despite optimal medical management

          -  No thrombolic or embolic events (e.g., cerebrovascular accident, including transient
             ischemic attacks) within the past 6 months

          -  No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within the past 4 weeks

          -  No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks

          -  No evidence or history of bleeding diathesis or coagulopathy

          -  No evidence of encephalopathy

          -  No condition that would impair the ability to swallow whole pills

          -  No history of malabsorption problems

          -  No significant traumatic injury within the past 4 weeks

          -  No serious non-healing wound, ulcer, or bone fracture

          -  No active clinically serious infection

          -  No known HIV infection

          -  No known or suspected allergy to sorafenib tosylate or any other study agent

        PRIOR CONCURRENT THERAPY:

          -  No prior cisplatin, carboplatin, or sorafenib tosylate

          -  No prior systemic chemotherapy for HCC

          -  No other prior systemic or locoregional therapy

          -  More than 4 weeks since prior major surgery or open biopsy

          -  No concurrent St. John's wort or rifampin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn G. Feun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>July 25, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2009</firstreceived_date>
  <firstreceived_results_date>July 18, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cisplatin or Carboplatin + Sorafenib</title>
          <description>Cisplatin : Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cisplatin or Carboplatin + Sorafenib</title>
          <description>Cisplatin : Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65" lower_limit="48" upper_limit="84"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Child-Pugh Score</title>
          <description>Child-Pugh score is used to assess the prognosis of chronic liver disease, mainly cirrhosis. Although it was originally used to predict mortality during surgery, it is now used to determine the prognosis, as well as the required strength of treatment and the necessity of liver transplantation.
Chronic liver disease is classified into Child-Pugh class A to C:
Child-Pugh A: Points (5-6); 1 year survival (100%); 2 year survival (85%) Child-Pugh B: Points (7-9); 1 year survival (81%); 2 year survival (57%) Child-Pugh C: Points (10-15); 1 year survival (45%); 2 year survival (35%)</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Child-Pugh A</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Child-Pugh B</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing Adverse Events</title>
        <description>The number of subjects experiencing adverse events after receiving protocol therapy.</description>
        <time_frame>36 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Of the 11 participants enrolled, 10 had results that were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin or Carboplatin + Sorafenib</title>
            <description>Cisplatin : Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Experiencing Adverse Events</title>
            <description>The number of subjects experiencing adverse events after receiving protocol therapy.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Clinical Benefit</title>
        <description>Number of patients achieving complete or partial response according to RECIST criteria</description>
        <time_frame>36 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Of the 11 participants enrolled, 10 had results that were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin or Carboplatin + Sorafenib</title>
            <description>Cisplatin : Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Patients Achieving Clinical Benefit</title>
            <description>Number of patients achieving complete or partial response according to RECIST criteria</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cisplatin or Carboplatin + Sorafenib</title>
          <description>Cisplatin : Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Esophagheal Bleeding</sub_title>
                <description>Patient had prior history of esophageal varices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoidal Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Feun MD</name_or_title>
      <organization>University of Miami Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-4981</phone>
      <email>lfeun@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
